| Literature DB >> 28740847 |
Orestis Ioannidis1, Loukiani Kitsikosta1, Dimitris Tatsis1, Ioannis Skandalos2, Aggeliki Cheva3, Aikaterini Gkioti4, Ioannis Varnalidis5, Savvas Symeonidis1, Natalia Antigoni Savvala1, Styliani Parpoudi1, George K Paraskevas6, Manousos George Pramateftakis1, Efstathios Kotidis1, Ioannis Mantzoros1, Konstantinos George Tsalis1.
Abstract
BACKGROUND: Fournier's gangrene (FG) is a rapidly evolving necrotizing fasciitis of the perineum and the genital area, the scrotum as it most commonly affects man in the vast majority of cases. It is polymicrobial in origin, due to the synergistic action of anaerobes and aerobes and has a very high mortality. There are many predisposing factors including diabetes mellitus, alcoholism, immunosuppression, renal, and hepatic disease. The prognosis of the disease depends on a lot of factors including but not limited to patient age, disease extent, and comorbidities. The purpose of the study is to describe the experience of a general surgery department in the management of FG, to present the multimodal and multidisciplinary treatment of the disease, to identify predictors of mortality, and to make general surgeons familiar with the disease.Entities:
Keywords: necrosis; perianal; perineum; polymicrobial; scrotum; surgical debridement
Year: 2017 PMID: 28740847 PMCID: PMC5502266 DOI: 10.3389/fsurg.2017.00036
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
Figure 1Skin necrosis of the scrotum (A), scrotum, perineal and perianal region (B) in males and of the genital, and perineal region (C) in a female.
Patient demographics and clinical presentation.
| Variable | Total | Non-survivors | Survivors | |
|---|---|---|---|---|
| Age (years) | 58.9 ± 11.3 | 57.4 ± 10.9 | 58.8 ± 11.9 | 0.749 |
| Male/female | 20/4 | 4/1 (80%/20%) | 16/3 | 0.822 |
| HR (bpm) | 93.1 ± 16.3 | 97 ± 18.2 | 93.3 ± 15.6 | 0.554 |
| RR (brpm) | 20.9 ± 5 | 23.6 ± 6.4 | 20 ± 4.6 | 0.168 |
| SAP (mmHg) | 103.1 ± 18.9 | 98 ± 19.2 | 104.3 ± 19.7 | 0.503 |
| DAP (mmHg) | 62.1 ± 11.7 | 60.3 ± 12 | 66 ± 11.4 | 0.412 |
| MAP (mmHg) | 78.8 ± 11.1 | 77 ± 11.9 | 82 ± 7.6 | 0.474 |
| Temperature (°C) | 37.9 ± 1.1 | 38.2 ± 1.3 | 37.9 ± 1.1 | 0.563 |
| Diuresis (cc) | 1,586 ± 593 | 1,400 ± 612 | 1,660 ± 611 | 0.436 |
| Time from symptoms to emergency department (days) | 2 (1) | 3 (1.5) | 2 (1) | 0.410 |
| Body surface (%) | 3 (2) | 3 (1.5) | 3 (3) | 0.528 |
| Sepsis | 18 (75%) | 4 (80%) | 14 (73.7%) | 0.772 |
| Severe sepsis | 9 (37.5%) | 2 (40%) | 7 (36.8%) | 0.897 |
| Septic shock | 3 (12.5%) | 1 (20%) | 2 (10.5%) | 0.521 |
Laboratory tests.
| Variable | Total | Non-survivors | Survivors | |
|---|---|---|---|---|
| Hemoglobin (g/dL) | 11.5 ± 1.4 | 9.8 ± 0.9 | 12 ± 1.1 | <0.001 |
| Hematocrit (%) | 33.9 ± 4.8 | 28.5 ± 3.8 | 35.3 ± 3.7 | 0.002 |
| PLT (K/μL) | 226,000 (222,500) | 149,000 (294,500) | 226,000 (229,000) | 0.506 |
| White blood cell (total/mm3) | 15,000 (8,360) | 17,600 (16,860) | 14,700 (9,700) | 0.619 |
| Glucose (mg/dL) | 100 (115) | 120 (105) | 100 (120) | 0.618 |
| Creatinine (mg/dL) | 0.75 (0.6) | 1.29 (1.2) | 0.75 (0.61) | 0.135 |
| Urea (mg/dL) | 33 (13.5) | 40 (71.5) | 32 (14) | 0.198 |
| Total protein (g/dL) | 4.85 ± 0.49 | 4.86 ± 0.58 | 4.8 ± 0.47 | 0.965 |
| Albumin (g/dL) | 2.44 ± 0.29 | 2.41 ± 0.27 | 2.44 ± 0.31 | 0.777 |
| Globulin (g/dL) | 2.63 ± 0.32 | 2.65 ± 0.36 | 2.62 ± 0.33 | 0.910 |
| Bilirubin (mg/dL) | 0.84 (0.62) | 0.88 (8.16) | 0.84 (0.6) | 0.934 |
| Gamma-glutamyl transferase (U/L) | 50 (37) | 50 (42) | 30 (38) | 0.9 |
| Alkaline phosphatase (U/L) | 99 (50) | 95 (401) | 99 (50) | 0.77 |
| ALT (U/L) | 24 (13) | 20 (9.5) | 26 (15) | 0.868 |
| AST (IU/L) | 26 (14) | 23 (70) | 29 (12) | 0.934 |
| Na+ (mmol/L) | 136 (7) | 131 (7) | 138 (6) | 0.183 |
| K+ (mmol/L) | 3.9 (0.3) | 4 (0.72) | 3.9 (0.3) | 0.707 |
| Ca (mg/dL) | 9.2 (1.3) | 9.1 (0.9) | 9.6 (1.7) | 0.465 |
| Lactate dehydrogenase (U/L) | 169 (140) | 138 (137.5) | 177 (136) | 0.77 |
| Creatine kinase (U/L) | 64 (62) | 50 (118) | 64 (46) | 0.967 |
| Prothrombin time (s) | 14.8 ± 2.9 | 17.1 ± 4.9 | 14.2 ± 2.5 | 0.251 |
| Activated partial thromboplastin time (s) | 32 (2) | 32 (0.95) | 32 (3) | 0.523 |
| International normalized ratio | 1.25 ± 0.24 | 1.43 ± 0.4 | 1.2 ± 0.13 | 0.255 |
| Cholesterol (mg/dL) | 210 (70) | 210 (65) | 225 (60) | 0.803 |
| C-reactive protein (mg/dL) | 3.2 (1.9) | 3.0 (2.1) | 3.2 (1.6) | 0.298 |
| PaCO2 (mmHg) | 32.5 ± 5.8 | 29.4 ± 5.1 | 32.9 ± 5.5 | 0.182 |
| PaO2 (mmHg) | 97.2 (19) | 92.1 (7.3) | 100 (18.9) | 0.143 |
| Bicarbonate (mmol/L) | 21.2 ± 1.9 | 20.8 ± 1.3 | 21.5 ± 2 | 0.595 |
| Lactic acid (mmol/L) | 1.36 ± 0.46 | 1.36 ± 0.53 | 1.35 ± 0.46 | 0.992 |
| pH | 7.36 ± 0.09 | 7.35 ± 0.15 | 7.37 ± 0.08 | 0.717 |
Comorbidities.
| Variable | Total (24) | Non-survivors (5) | Survivors (19) | |
|---|---|---|---|---|
| Pulmonary disease | 4 (16.6%) | 2 (40%) | 2 (10.5%) | 0.179 |
| Renal disease | 2 (8.3%) | 1 (20%) | 1 (5.2%) | 0.380 |
| Heart disease | 5 (20.8%) | 1 (20%) | 4 (21.0%) | 0.959 |
| Liver disease | 2 (8.3%) | 0(0%) | 2 (10.5%) | 0.449 |
| Diabetes mellitus | 7 (29.1%) | 2 (40%) | 5 (26.3%) | 0.608 |
| Hypertension | 6 (25%) | 1 (20%) | 5 (26.3%) | 0.772 |
| Hyperlipidemia | 7 (29.1%) | 1 (20%) | 6 (31.5%) | 0.612 |
| Malignancy | 2 (8.3%) | 2 (40%) | 0 (0%) | 0.036 |
| Peripheral vascular disease | 6 (25%) | 1 (20%) | 5 (26.3%) | 0.772 |
| Psychiatric disease | 2 (8.3%) | 1 (20%) | 1 (5.2%) | 0.380 |
| Obesity | 5 (20.8%) | 1 (20%) | 4 (21.0%) | 0.959 |
| Immunosuppression | 4 (16.6%) | 2 (40%) | 2 (10.5%) | 0.179 |
| Smoking | 9 (37.5%) | 1 (20%) | 8 (42.1%) | 0.615 |
| Alcoholism | 5 (20.8%) | 0 (0%) | 5 (26.3%) | 0.544 |
| Charlson Comorbidity Index | 2 (1.5) | 3 (3.5) | 2 (2) | 0.084 |
| Age Adjusted Charlson Comorbidity Index | 3 (1) | 3 (2) | 3 (1) | 0.156 |
| Body mass index (kg/cm2) | 27 (9.5) | 29 (24.5) | 26 (10) | 0.482 |
Figure 2Pelvic X-ray showing the presence of air in the soft tissue.
Etiology and microbiology.
| Variable | Total (24) | Non-survivors (5) | Survivors (19) | |
|---|---|---|---|---|
| Trauma | 3 (12.5%) | 1 (20%) | 2 (10.5%) | 0.521 |
| Urogenital | 4 (16.6%) | 1 (20%) | 3(15.7%) | 0.822 |
| Skin infection–abscess | 5 (20.8%) | 1 (20%) | 4 (21.0%) | 0.959 |
| Idiopathic | 2 (8.3%) | 0 (0%) | 2 (10.5%) | 0.449 |
| Colorectal | 10 (41.6%) | 2 (40%) | 8 (42.1%) | 0.668 |
| Gram (−) | 17 (70.8%) | 4 (80%) | 13 (68.4%) | 0.612 |
| Gram (+) | 6 (25%) | 1 (20%) | 5 (26.3%) | 0.772 |
| Anaerobes | 11 (45.8%) | 2 (40%) | 9 (47.4%) | 0.769 |
| Polymicrobial infection | 13 (54.1%) | 3(60%) | 10 (52.6%) | 0.769 |
Figure 3Extended surgical debridement of the scrotal, perineal, and perianal area.
Figure 4Rectal diversion device.
Figure 5Granulomatosis of the surgical wounds following extended surgical debridement and daily dressing changes of the scrotum, perineal, and perianal region (A), of the scrotum and perineum (B), and of the scrotum and left inguinal region (C).
Intervention and hospitalization.
| Variable | Total (24) | Non-survivors (5) | Survivors (19) | |
|---|---|---|---|---|
| Time from emergency department to OR (h) | 4 (2) | 3 (2) | 4 (2.75) | 0.086 |
| Surgical time (min) | 55 (21.5) | 60 (27.5) | 55 (27) | 0.647 |
| Number of surgical debridements | 1 (1) | 2 (2) | 1.5 (1) | 0.631 |
| Transfusion (RBC) | 1 (2) | 1 (2) | 1 (2) | 0.405 |
| Vasoactive drugs | 7 (29.1%) | 2(40%) | 5 (26.3%) | 0.608 |
| Colostomy | 4(16.7%) | 1 | 3 | 0.822 |
| Rectal diversion | 2(8.3%) | 0 | 2 | 0.449 |
| Urostomy | 0 (0%) | 0 | 0 | 1 |
| Hyperbaric oxygen | 3 (12.5%) | 0 | 3 | 0.342 |
| Vacuum-assisted closure | 1 | 0 | 1 | 0.600 |
| Total hospitalization (days) | 27(38.5) | 3 (16.5) | 40 (39) | 0.008 |
| Intensive care unit stay (days) | 0 (1.5) | 0 (1.5) | 0 (2) | 0.961 |
| Surgical department stay (days) | 16 (34.5) | 3 (18) | 25 (34) | 0.075 |
Figure 6Histopathologic findings in Fournier’s gangrene revealing neutrophilic exudate and epidermis necrosis (A), thrombosis of vessels (B), and abscessation and necrosis of subcutaneous fat tissue (C) (hematoxylin and eosin staining ×200).
Severity index and prognostic scores.
| Variable | Total | Non-survivors | Survivors | |
|---|---|---|---|---|
| APACHE II | 10 (3.5) | 14 (12) | 10 (2) | 0.142 |
| FGSI | 5 (5) | 5 (9) | 2 (4) | 0.179 |
| Uludag FGSI | 6 (9) | 9 (6) | 5 (3) | 0.062 |
| LRINEC | 5 (4) | 7 (4.5) | 5 (4) | 0.145 |
Figure 7Skin graft reconstruction immediately after surgery (A), long-term result after skin graft (B), and wound healing by secondary intention (C). The patients are in accordance with Figure 5.